Scoop: Tur­ing CEO and Shkre­li al­ly Ron Tilles is out as CEO, R&D chief Sali­nas takes the helm and board vote looms

Regime change of some sort is un­der­way at the con­tro­ver­sial Tur­ing Phar­ma­ceu­ti­cals.

Tipped off on Fri­day that CEO and co-founder Ron Tilles — a close as­so­ciate of for­mer Tur­ing CEO Mar­tin Shkre­li — was leav­ing the top post, the biotech con­firmed to End­points News Sun­day evening that Tilles is be­ing re­placed by chief sci­en­tif­ic of­fi­cer Eliseo Sali­nas. Here’s the state­ment:

“Tur­ing Phar­ma­ceu­ti­cals has ap­point­ed Dr. Eliseo Sali­nas, MD, MSc as in­ter­im CEO. Dr. Sali­nas will guide Tur­ing as it moves for­ward to max­i­mize Dara­prim’s suc­cess as the pri­ma­ry al­ter­na­tive for the treat­ment of tox­o­plas­mo­sis in com­bi­na­tion with a sul­fon­amide, and to ad­vance the promis­ing pipeline of new com­pounds for se­vere par­a­sitic in­fec­tions, while Mr. Tilles will re­main a mem­ber of Tur­ing’s board.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER